JPMorgan analyst James Gordon raised the firm’s price target on Argenx to EUR 500 from EUR 480 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARGX:
- Argenx included on Wells Fargo’s Tactical Ideas List for Q1 2023
- Wells Fargo upgrades Immunovant to Overweight, raises price target to $27
- argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
- Argenx price target raised to $478 from $471 at Stifel
- Piper recommends ‘down market cap’ biotech exposure for 2023